Abstract
Bayer HealthCare has agreed to acquire US-based Conceptus in a deal that values the company at approximately US$1.1 B. With the acquisition, Bayer will gain Conceptus’ sole marketed product Essure®, a non-surgical, hormone-free permanent birth control method for women that was approved by the US FDA in 2002. The offer price represents a premium of 19.7% over Conceptus’ closing price prior to the announcement of the transaction. Bayer is the leading player in the contraceptives market but is facing generic competition on its blockbuster Yaz® (drospirenone/ethinyl oestradiol) franchise.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
